Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia

Mirjana Gotic, Miklos Egyed, Liana Gercheva, Krzysztof Warzocha, Hans Michael Kvasnicka, Heinrich Achenbach, Jingyang Wu, Mirjana Gotic, Miklos Egyed, Liana Gercheva, Krzysztof Warzocha, Hans Michael Kvasnicka, Heinrich Achenbach, Jingyang Wu

Abstract

Essential thrombocythaemia (ET) is a rare myeloproliferative neoplasm. This multicentre, Phase 3b, randomised, open-label, non-inferiority study investigated the cardiac safety, efficacy and tolerability of first-line treatment with anagrelide or hydroxyurea in high-risk ET patients for up to 3 years. Eligible patients aged ≥ 18 years with a diagnosis of high-risk ET confirmed by bone marrow biopsy within 6 months of randomisation received anagrelide (n = 75) or hydroxyurea (n = 74), administered twice daily. Treatment dose for either compound was titrated to the lowest dose needed to achieve a response. Planned primary outcome measures were change in left ventricular ejection fraction from baseline over time and platelet count at Month 6. Planned secondary outcome measures were platelet count change from baseline at Months 3 and 36; percentage of patients with complete or partial response; time to complete or partial response; number of patients with thrombohaemorrhagic events; and changes in white blood cell count or red blood cell count over time. Neither treatment altered cardiac function. There were no significant differences in adverse events between treatment groups, and no reports of malignant transformation. The incidence of disease-related thrombotic or haemorrhagic events was numerically higher in anagrelide-treated patients. Both treatments controlled platelet counts at 6 months, with the majority of patients experiencing complete or partial responses. In conclusion, these results suggest that long-term treatment with anagrelide is not associated with adverse effects on cardiac function. This is one of the few studies using left ventricular ejection fraction assessment and central biopsy reading to confirm the diagnosis of ET.Trial registration number: Clinicaltrials.gov NCT00202644.

Keywords: Anagrelide; Cardiac safety; Essential thrombocythaemia; Hydroxyurea; Platelet counts.

Conflict of interest statement

HMK received honoraria from Shire International GmbH (a member of the Takeda group of companies), Novartis and Incyte, and research funding from Shire and Incyte. HA and JW are employees of Shire International GmbH, a member of the Takeda group of companies. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Patient disposition. LVEF, left ventricular ejection fraction; FAS, full analysis set; PP, per protocol

References

    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544.
    1. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26(Suppl 5):v85–99. doi: 10.1093/annonc/mdv203.
    1. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. European Journal of Haematology. 2014;92(4):289–297. doi: 10.1111/ejh.12256.
    1. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–2513. doi: 10.1182/blood-2014-05-579136.
    1. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings. 2006;81(2):159–166. doi: 10.4065/81.2.159.
    1. Smith BB, Nuttall GA, Pruthi RK, Joyce DL, Schuldes MS, Smith MM. A novel approach to essential thrombocythemia and cardiac surgery. Annals of Thoracic Surgery. 2017;103(3):e249–e250. doi: 10.1016/j.athoracsur.2016.08.065.
    1. Vianello F, Cella G, Osto E, Ballin A, Famoso G, Tellatin S, et al. Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: The missing piece in the puzzle of their increased cardiovascular risk? American Journal of Hematology. 2015;90(2):109–113. doi: 10.1002/ajh.23881.
    1. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069. doi: 10.1038/s41375-018-0077-1.
    1. Tefferi A, Barbui T. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia. 2013;27(8):1617–1620. doi: 10.1038/leu.2013.99.
    1. Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology. 2010;149(3):352–375. doi: 10.1111/j.1365-2141.2010.08122.x.
    1. European Medicines Agency (EMA) (2017). Xagrid Summary of Product Characteristics. Retrieved September 28, 2020, from .
    1. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood. 2002;99(5):1602–1609. doi: 10.1182/blood.V99.5.1602.
    1. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121(10):1720–1728. doi: 10.1182/blood-2012-07-443770.
    1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine. 2005;353(1):33–45. doi: 10.1056/NEJMoa043800.
    1. Felker G, O'Connor C. Ionotropic therapy for heart failure: An evidence-based review. American Heart Journal. 2001;142(3):393–401. doi: 10.1067/mhj.2001.117606.
    1. Thackray S, Easthaugh J, Freemantle N, Cleland J. The effectiveness and realtive effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heat failure: A meta-regression analysis. European Journal of Heart Failure. 2002;4:515–529. doi: 10.1016/S1388-9842(02)00041-7.
    1. Pescatore SL, Lindley C. Anagrelide: A novel agent for the treatment of myeloproliferative disorders. Expert Opinion on Pharmacotherapy. 2000;1(3):537–546. doi: 10.1517/14656566.1.3.537.
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haemopoietic and lymphoid tissues, 2nd edition. 4. Lyon: IARC Press; 2008.
    1. Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leukemia Research. 2011;35(12):1557–1563. doi: 10.1016/j.leukres.2011.06.030.
    1. Tortorella G, Piccin A, Tieghi A, Marcheselli L, Steurer M, Gastl G, et al. Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study. Leukemia Research. 2015;39(6):592–598. doi: 10.1016/j.leukres.2015.03.014.
    1. Dombi P, Illes A, Demeter J, Homor L, Simon Z, Karadi E, et al. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. European Journal of Haematology. 2017;98(2):106–111. doi: 10.1111/ejh.12806.
    1. Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, et al. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 2015;29(6):1344–1349. doi: 10.1038/leu.2015.87.
    1. Bjorkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. Journal of Clinical Oncology. 2011;29(17):2410–2415. doi: 10.1200/JCO.2011.34.7542.
    1. Choragudi NL, Prakash AM, Sun Y, Prasad P, Chiaramida SA, Lucariello RJ. Comparison of echocardiography with technetium 99m-gated single photon emission computed tomography as diagnostic tools for left ventricular ejection fraction. Echocardiography. 2001;18(8):627–632. doi: 10.1046/j.1540-8175.2001.00627.x.
    1. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112(24):3738–3744. doi: 10.1161/CIRCULATIONAHA.105.561423.
    1. Marwick TH. Ejection fraction pros and cons: JACC state-of-the-art review. Journal of the American College of Cardiology. 2018;72(19):2360–2379. doi: 10.1016/j.jacc.2018.08.2162.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren